NASDAQ:LGND Ligand Pharmaceuticals (LGND) Stock Forecast, Price & News $73.76 -0.52 (-0.70%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$73.40▼$74.8750-Day Range$69.53▼$79.3352-Week Range$57.77▼$109.00Volume115,026 shsAverage Volume110,376 shsMarket Capitalization$1.27 billionP/E Ratio58.54Dividend YieldN/APrice Target$112.25 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Ligand Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside52.2% Upside$112.25 Price TargetShort InterestBearish5.03% of Float Sold ShortDividend StrengthN/ASustainability-1.57Upright™ Environmental ScoreNews Sentiment0.66Based on 10 Articles This WeekInsider TradingSelling Shares$1.35 M Sold Last QuarterProj. Earnings Growth-23.26%From $3.74 to $2.87 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.56 out of 5 starsMedical Sector80th out of 987 stocksPharmaceutical Preparations Industry30th out of 477 stocks 3.5 Analyst's Opinion Consensus RatingLigand Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $112.25, Ligand Pharmaceuticals has a forecasted upside of 52.2% from its current price of $73.76.Amount of Analyst CoverageLigand Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.03% of the float of Ligand Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverLigand Pharmaceuticals has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Ligand Pharmaceuticals has recently increased by 0.65%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldLigand Pharmaceuticals does not currently pay a dividend.Dividend GrowthLigand Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreLigand Pharmaceuticals has received a 67.85% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antihypertensives (C02)", "Pneumococcal vaccines", "Quinolones", "Fosphenytoin", "Antifungal medication (D01) ", and "Bevacizumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Ligand Pharmaceuticals is -1.57. Previous Next 2.6 News and Social Media Coverage News SentimentLigand Pharmaceuticals has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Ligand Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest12 people have searched for LGND on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Ligand Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ligand Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,348,898.00 in company stock.Percentage Held by Insiders10.40% of the stock of Ligand Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions87.16% of the stock of Ligand Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Ligand Pharmaceuticals are expected to decrease by -23.26% in the coming year, from $3.74 to $2.87 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ligand Pharmaceuticals is 58.54, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 139.23.Price to Earnings Ratio vs. SectorThe P/E ratio of Ligand Pharmaceuticals is 58.54, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 100.68.Price to Earnings Growth RatioLigand Pharmaceuticals has a PEG Ratio of 1.00. PEG Ratios around 1 indicate that a company is correctly valued.Price to Book Value per Share RatioLigand Pharmaceuticals has a P/B Ratio of 2.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ligand Pharmaceuticals (NASDAQ:LGND) StockLigand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.Read More Receive LGND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address LGND Stock News HeadlinesJune 9, 2023 | finance.yahoo.comIs Ligand Pharmaceuticals (LGND) Stock Outpacing Its Medical Peers This Year?June 8, 2023 | markets.businessinsider.comLigand Pharma (LGND) Gets a Buy from BarclaysJune 9, 2023 | UNKNOWN (Ad)This Company Is Solving A Multi-Billion Dollar Problem!This Little Known NASDAQ Stock is Solving a Multi-Billion Dollar Problem!June 7, 2023 | americanbankingnews.comLigand Pharmaceuticals (NASDAQ:LGND) Shares Down 5.4% June 6, 2023 | finance.yahoo.comUnitedHealth (UNH) Intends to Buy Amedisys to Boost Home-HealthJune 6, 2023 | finance.yahoo.comLGND or ILMN: Which Is the Better Value Stock Right Now?June 5, 2023 | finance.yahoo.comOncorus (ONCR) Dips 37% on Layoff Plan & Bankruptcy ThreatJune 5, 2023 | finance.yahoo.comSermonix Pharmaceuticals Shares ASCO Poster Presentation on Longer Patient Follow-up Results for ELAINE-2 Study in ESR1-mutated Metastatic Breast CancerJune 9, 2023 | UNKNOWN (Ad)This Company Is Solving A Multi-Billion Dollar Problem!This Little Known NASDAQ Stock is Solving a Multi-Billion Dollar Problem!June 3, 2023 | americanbankingnews.comLigand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $144.00 at HC WainwrightJune 2, 2023 | msn.comHC Wainwright & Co. Reiterates Ligand Pharmaceuticals, Inc. - Class B (LGND) Buy RecommendationJune 1, 2023 | finance.yahoo.comBiohaven (BHVN) Stock up 8% on Encouraging Pipeline UpdatesMay 27, 2023 | americanbankingnews.comLigand Pharmaceuticals (NASDAQ:LGND) Upgraded to Buy at StockNews.comMay 25, 2023 | finance.yahoo.comSermonix Pharmaceuticals to Share Longer Patient Follow-up Results for ELAINE-2 in Poster Presentation at ASCO 2023May 24, 2023 | finance.yahoo.comHas Anebulo Pharmaceuticals (ANEB) Outpaced Other Medical Stocks This Year?May 24, 2023 | finance.yahoo.comWall Street Analysts Think Ligand (LGND) Could Surge 44.42%: Read This Before Placing a BetMay 20, 2023 | americanbankingnews.comJohn W. Kozarich Sells 4,444 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) StockMay 20, 2023 | americanbankingnews.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives $101.67 Average PT from AnalystsMay 19, 2023 | benzinga.comDirector of Ligand Pharmaceuticals Makes $343K SaleMay 16, 2023 | markets.businessinsider.comViking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 TrialMay 16, 2023 | finance.yahoo.comHere's Why Biogen (BIIB) Stock is Up 12.6% This Year So FarMay 16, 2023 | finance.yahoo.comLigand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)May 13, 2023 | americanbankingnews.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Director Sells $490,596.48 in StockMay 10, 2023 | fool.comLigand Pharmaceuticals (NASDAQ: LGND)May 8, 2023 | finance.yahoo.comWall Street Analysts Believe Ligand (LGND) Could Rally 38.66%: Here's is How to TradeMay 8, 2023 | finance.yahoo.comLigand (LGND) Up 3% on Raised '23 View, Beats on Q1 EarningsMay 6, 2023 | finance.yahoo.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies AheadSee More Headlines LGND Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LGND Company Calendar Last Earnings5/04/2023Today6/09/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:LGND CUSIP53220K50 CIK886163 Webwww.ligand.com Phone(858) 550-7500Fax858-550-1826Employees154Year FoundedN/APrice Target and Rating Average Stock Price Forecast$112.25 High Stock Price Forecast$144.00 Low Stock Price Forecast$90.00 Forecasted Upside/Downside+52.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$1.26 Trailing P/E Ratio58.49 Forward P/E Ratio19.71 P/E Growth1Net Income$-33,360,000.00 Net Margins11.00% Pretax Margin46.22% Return on Equity3.44% Return on Assets2.66% Debt Debt-to-Equity RatioN/A Current Ratio3.32 Quick Ratio3.18 Sales & Book Value Annual Sales$196.24 million Price / Sales6.49 Cash Flow$5.02 per share Price / Cash Flow14.69 Book Value$35.37 per share Price / Book2.08Miscellaneous Outstanding Shares17,270,000Free Float15,477,000Market Cap$1.27 billion OptionableOptionable Beta1.07 Key ExecutivesTodd C. DavisChief Executive Officer & DirectorMatthew Edward KorenbergPresident & Chief Operating OfficerOctavio EspinozaChief Financial OfficerSimon LatimerInvestors Relations ManagerAudrey Warfield-GrahamChief People OfficerKey CompetitorsOPKO HealthNASDAQ:OPKMannKindNASDAQ:MNKDDynavax TechnologiesNASDAQ:DVAXInnovivaNASDAQ:INVAIronwood PharmaceuticalsNASDAQ:IRWDView All CompetitorsInsiders & InstitutionsMacquarie Group Ltd.Bought 17,387 shares on 6/1/2023Ownership: 4.736%ProShare Advisors LLCSold 409 shares on 5/26/2023Ownership: 0.020%Ameriprise Financial Inc.Sold 2,549 shares on 5/22/2023Ownership: 0.767%JPMorgan Chase & Co.Sold 2,677,744 shares on 5/18/2023Ownership: 0.278%New York State Common Retirement FundSold 2,900 shares on 5/18/2023Ownership: 0.046%View All Insider TransactionsView All Institutional Transactions LGND Stock - Frequently Asked Questions Should I buy or sell Ligand Pharmaceuticals stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LGND shares. View LGND analyst ratings or view top-rated stocks. What is Ligand Pharmaceuticals' stock price forecast for 2023? 4 Wall Street analysts have issued twelve-month price objectives for Ligand Pharmaceuticals' stock. Their LGND share price forecasts range from $90.00 to $144.00. On average, they predict the company's stock price to reach $112.25 in the next year. This suggests a possible upside of 52.3% from the stock's current price. View analysts price targets for LGND or view top-rated stocks among Wall Street analysts. How have LGND shares performed in 2023? Ligand Pharmaceuticals' stock was trading at $66.80 at the beginning of the year. Since then, LGND shares have increased by 10.3% and is now trading at $73.70. View the best growth stocks for 2023 here. When is Ligand Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our LGND earnings forecast. How were Ligand Pharmaceuticals' earnings last quarter? Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced its earnings results on Thursday, May, 4th. The biotechnology company reported $2.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.89 by $1.39. The biotechnology company had revenue of $43.98 million for the quarter, compared to the consensus estimate of $33.55 million. Ligand Pharmaceuticals had a trailing twelve-month return on equity of 3.44% and a net margin of 11.00%. The company's quarterly revenue was up 20.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.15 earnings per share. What ETFs hold Ligand Pharmaceuticals' stock? ETFs with the largest weight of Ligand Pharmaceuticals (NASDAQ:LGND) stock in their portfolio include Invesco Dynamic Pharmaceuticals ETF (PJP), iShares Genomics Immunology and Healthcare ETF (IDNA), Virtus LifeSci Biotech Products ETF (BBP), Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Franklin Genomic Advancements ETF (HELX) and Pacer US Small Cap Cash Cows 100 ETF (CALF). What guidance has Ligand Pharmaceuticals issued on next quarter's earnings? Ligand Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share guidance of $4.60-$4.75 for the period, compared to the consensus earnings per share estimate of $3.52. The company issued revenue guidance of $124.00 million-$128.00 million, compared to the consensus revenue estimate of $128.57 million. What is John L. Higgins' approval rating as Ligand Pharmaceuticals' CEO? 1 employees have rated Ligand Pharmaceuticals Chief Executive Officer John L. Higgins on Glassdoor.com. John L. Higgins has an approval rating of 100% among the company's employees. This puts John L. Higgins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Ligand Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Cisco Systems (CSCO), Illumina (ILMN) and Gilead Sciences (GILD). What is Ligand Pharmaceuticals' stock symbol? Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND." Who are Ligand Pharmaceuticals' major shareholders? Ligand Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.52%), Macquarie Group Ltd. (4.74%), Macquarie Group Ltd. (4.74%), State Street Corp (3.74%), Villere ST Denis J & Co. LLC (2.80%) and Dimensional Fund Advisors LP (2.74%). Insiders that own company stock include Andrew Reardon, Charles S Berkman, John L Higgins, John W Kozarich, Matthew W Foehr, Octavio Espinoza, Stephen L Sabba and Todd C Davis. View institutional ownership trends. How do I buy shares of Ligand Pharmaceuticals? Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ligand Pharmaceuticals' stock price today? One share of LGND stock can currently be purchased for approximately $73.70. How much money does Ligand Pharmaceuticals make? Ligand Pharmaceuticals (NASDAQ:LGND) has a market capitalization of $1.27 billion and generates $196.24 million in revenue each year. The biotechnology company earns $-33,360,000.00 in net income (profit) each year or $1.26 on an earnings per share basis. How many employees does Ligand Pharmaceuticals have? The company employs 154 workers across the globe. How can I contact Ligand Pharmaceuticals? Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The official website for the company is www.ligand.com. The biotechnology company can be reached via phone at (858) 550-7500, via email at investors@ligand.com, or via fax at 858-550-1826. This page (NASDAQ:LGND) was last updated on 6/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.